{"id":"W4412166483","doi":"10.1017/cjn.2025.10200","title":"P.016 Secondary immunodeficiencies in ocrelizumab - versus rituximab-treated persons with relapsing Multiple Sclerosis","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Vancouver Biotech (Canada)","funders":"","keywords":"Ocrelizumab; Multiple sclerosis; Medicine; Rituximab; Immunology; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006017943,0.0001042274,0.000206512,0.0002883518,0.0001583364,0.0002767792,0.0001551024,0.0002510795,0.003199258],"category_scores_gemma":[0.001447243,0.00007233996,0.0005015762,0.0002782954,0.0001391645,0.0002092872,0.0001833494,0.0002686383,0.0002334341],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002486837,"about_ca_system_score_gemma":0.0001783347,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007337827,"about_ca_topic_score_gemma":0.0007060011,"domain_scores_codex":[0.9996669,0.0001131128,0.00004121734,0.00007232737,0.00005969055,0.00004665733],"domain_scores_gemma":[0.9991544,0.0002345744,0.0004561812,0.00001871471,0.0000366099,0.00009955095],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003731563,0.0001132905,0.9862715,0.0001093254,0.0001949974,0.0002561203,0.00005005635,0.00009484516,0.0003369464,0.0000502206,0.0003936385,0.008397409],"study_design_scores_gemma":[0.0002924487,0.003191001,0.9921585,0.00007863453,0.0002211594,0.001937158,0.0001613473,0.0006362345,0.0002362678,0.00005668917,0.001025791,0.000004806963],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974297,0.001554132,0.00005580609,0.00005420996,0.0000156083,0.00001494305,0.000258456,0.000002324188,0.0006148482],"genre_scores_gemma":[0.9996123,0.0001256525,0.00003425837,0.00002327627,0.00001475232,0.000009055091,0.0001041394,4.726721e-7,0.00007610234],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003199258,"threshold_uncertainty_score":0.01070255,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02657094875320814,"score_gpt":0.2324510374746119,"score_spread":0.2058800887214038,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}